Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women

Tohoku Journal of Experimental Medicine

Volumn 214, Issue 1, 2008, Pages 51-59

  Abe, Yoshihiro ^a   Ishikawa, Hitoshi ^a   Fukao, Akira ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Biomarker; NTX; Osteoporosis; Postmenopausal women; Signal to noise ratio

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BENETO; BIOCHEMICAL MARKER; CALCIUM CARBONATE; PLACEBO; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

AGED; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MONITORING; DRUG RESPONSE; FEMALE; HUMAN; JAPANESE; MORNING DOSAGE; OPEN STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO; TREATMENT RESPONSE;

EID: 38749134130     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.214.51     Document Type: Article

References (37)

1. Alvarez, L., Ricós, C., Peris, P., Guañabens, N., Monegal, A., Pons, F. & Ballesta, A. M. (2000) Components of biological variation of biochemical markers of bone turnover in Paget's bone disease. Bone, 26, 571-576.
2. Bjamason, N.H. & Christiansen, C. (2000) Early response in biochemical markers predict long-term response in bone mass during hormone replacement therapy in early post-menopausal women. Bone, 26, 561-569.
3. Bland, J.M. & Altman, D.G. (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet, 1, 307-310.
4. Blumsohn, A., Herrington, K., Hannon, R., Shao, P., Eyre, D.R. & Eastell, R. (1994) The effect of calcium supplementation on the circadian rhythm of bone resorption. J. Clin. Endocrinol. Metab., 79, 730-735.
5. Brewin, C.R. & Bradley, C. (1989) Patient preferences and randomized clinical trials. Br. Med. J., 299, 313-315.
6. Chesnut, C.H., III, Bell, N.H., Clark, G.S., Drinkwater, B.L., English, S.C., Johnson, C.C., Jr., Notelovitz, M., Rosen, C., Cain, D.F., Flessland, K.A. & Mallinak, N.J. (1997) Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predict response of bone mineral density. Am. J. Med., 102, 29-37.
7. Clemens, J.D., Herrick, M.V., Singer, F.R. & Eyre, D.R. (1997) Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin. Chem., 43, 2058-2063.
8. Clowes, J.A., Peel, N.F.A. & Eastell, R. (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab., 89, 1117-1123.
9. Delmas, P.D., Vrijens, B., Roux, C., Le-Moigne-Amrani, A., Eastell, R., Grauer, A., Watts, N.B., Pols, H.A.P., Ringe, J.D. & Cahall, D. (2003) A reinforcement message based on bone turnover marker response influence long-term persistence with risedronate in osteoporosis: The IMPACT study. J. Bone Miner. Res., 18, (Suppl. 2), S374.
10. Eastell, R., Mallinak, N., Weiss, S., Ettinger, M., Pettinger, M., Cain, D., Flessland, K. & Chesnut, C., III. (2000) Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J. Bone Miner. Res., 15, 594-598.
11. Eastell, R., Barton, I., Hannon, R.A., Chines, A., Gamero, P. & Delmas, P.D. (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res., 18, 1051-1056.
12. Eisman, J.A. (1999) Genetics of osteoporosis. Endocr. Rev., 20, 788-804.
13. Fall, P.M., Kennedy, D., Smith, J.A., Seibel, M.J. & Raisz, L.G. (2000) Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without, hormone replacement therapy and in men. Osteoporos Int., 11, 481-485.
14. Fink, E., Cromier, C., Steinmetz, P., Kindermans, C., Le Bouc, Y. & Souberbielle, J.-C. (2000) Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int., 11, 295-303.
15. Fogelman, I., Ribot, C., Smith, R., Ethgen, D., Sod, E. & Reginster, J.Y.D. (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab., 85, 1895-1900.
16. Fukunaga, M., Kushida, K., Kishimoto. H., Shiraki, M., Taketani, Y., Minaguchi, H., Inoue, T., Morita, R., Morii, H., Yamamoto, K., Ohashi, Y. & Orimo, H. (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int., 13, 971-979.
17. Greenspan, S., Parker, R., Ferguson, L., Rosen, H., Maitland-Ramsey, L. & Karpf, D. (1998a) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J. Bone Miner. Res., 13, 1431-1438.
18. Greenspan, S., Morgan, J., Furstoss, K., Rafferty, J., Carpenter, R., Pettinger, M. & Clemens, J. (1998b) Measuring response to alendronate therapy in elderly women by serum cross-linked N-telopeptides (NTX) immunoassay. J. Bone Miner. Res., 23 (Suppl. 5), SA431.
19. Greenspan, S.L., Rosan, H.N. & Parker, R.A. (2000) Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J. Clin. Endocrinol. Metab., 85, 3537-3540.
20. Hannon, R., Blumsohn, A., Naylor, K. & Eastell, R. (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J. Clin. Endocrinol. Metab., 13, 1124-1133.
21. Hannon, R. & Eastell, R. (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int., Suppl. 6, S30-S44.
22. Harrington, J.T., Ste-Marie, L.-G., Brandi, M.L., Civitelli, R., Fardellone, P., Grauer, A., Barton, I. & Boonen, S. (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif. Tissue Int., 74, 129-135.
23. Harris, S.T., Watts, N.B., Genant, H.K., McKeever, C.D., Hangartner, T., Keller, M., Chesnut, C.H., III., Brown, J., Eriksen, E.F., Hoseyni, M.S., Axelrod, D.W. & Miller, P.D. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA, 282, 1344-1352.
24. Hochberg, M.C., Ross, P.D., Black, D., Cummings, S.R, Genant, H.K., Nevitt, M.C., Barrett-Connor, E., Musliner, T. & Thompson, D. (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis. Rheum., 42, 1246-1254.
25. Iki, M., Kagaminori, S., Kagawa, Y., Matsuzaki, T., Yoneshima, H. & Marumo, F. for JPOS study. (2001) Bone mineral density of the spine, hip and distal forearm in representation live samples of the Japanese female population: Japanese population-based osteoporosis (JPOS) study. Osteoporos Int., 12, 529-537.
26. Karmatschek, M., Maier, I., Seibel, M.J., Woitge, H.W, Ziegler, R. & Armbruster, F.P. (1997) Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. Clin. Chem., 43, 2076-2082.
27. Kushida, K., Fukunaga,, M., Kishimoto, H., Shiraki, M., Itabashi, A., Inoue, T., Kaneda, K., Morii, H., Nawata, H., Yamamoto, K., Ohashi, Y. & Orimo, H. (2004) Risedronate Phase III Research Group. A comparison of incidence of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J. Bone Miner. Metab., 22, 469-478.
28. Leung, J.Y.Y., Ho, A.Y.Y., Ip, T.P., Lee, G. & Kung, A.W.C. (2005) The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. Bone, 36, 358-364.
29. Nohara, T., Kamei, T. & Ohta, A. (2006) Accelerated decrease in bone mineral density in women aged 52-57 years. Tohoku J. Exp. Med., 210, 341-347.
30. Ogura, Y., Gonsho, A., Cyong, J.-C. & Orimo, H. (2004) Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption. J. Bone Miner. Metab., 22, 120-126.
31. Roux, C., Seeman, E., Eastell, R., Adachi, J., Jackson, R.D., Felsenberg, D., Songcharoen, S., Rizzoli, R., DiMunno, O., Horlait, S., Valent, D. & Watts, N.B. (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr. Med. Res. Opin., 20, 433-439.
32. Seibel, M.J. (2000) Molecular markers of bone turnover: Biochemical technical and analytical aspects. Osteoporos Int., 10 (Suppl. 6), S18-S29.
33. Shiraki, M., Kushida, K., Fukunaga, M., Kishimoto, H., Taga, M., Nakamura, T., Kaneda, K., Minaguchi, H., Taketani, Y., Inoue, T., Morii, H., Tomita, A., Yamamoto, K., Nagata, Y., Nakashima, M. & Orimo, H. (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int., 10, 183-192.
34. Shiraki, M., Fukunaga, M., Kushida, K., Kishimoto, H., Taketani, Y., Minaguchi, H., Inoue, T., Morita, R., Morii, H., Yamamoto, K., Ohashi, Y. & Orimo, H. (2002) A double-blind dose ranging study of risedronate in Japanese patients with involutional osteoporosis [abstract P93SU]. Osteoporos Int., 13 (Suppl. 1), S33.
35. Swaminathan, R. (2001) Biochemical markers of bone turnover. Clin. Chim. Acta, 313, 95-105.
36. Takahashi, M., Kawana, K. & Nagano, A. (2002) Biological variability of biochemical markers of bone turnover in healthy women. Endocr. J., 28, 257-264.
37. Woitge, H.W., Pecherstorfer, M., Li, Y., Keck, A.-V., Horn, E., Ziegler, R. & Seibel, M. (1999), Novel serum markers of bone resorption: clinicai assessment and comparison with established urinary indices. J. Bone Miner. Res., 14, 792-801.